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Abstract 
Background: Sex workers have high incidences of HIV and other sexually transmitted diseases. Although, inter‑
ventions targeting sex workers have shown to be effective, evidence on which strategies are most cost‑effective is 
limited. This study aims to systematically review evidence on the cost‑effectiveness of sexual health interventions for 
sex workers on a global level. It also evaluates the quality of available evidence and summarizes the drivers of cost 
effectiveness.
Methods: A search of published articles until May 2018 was conducted. A search strategy consisted of key words, 
MeSH terms and other free text terms related to economic evaluation, sex workers and sexual and reproductive 
health (SRH) was developed to conduct literature search on Medline, Web of Science, Econlit and the NHS Economic 
Evaluation Database. The quality of reporting the evidence was evaluated using the CHEERS checklist and drivers of 
cost‑effectiveness were reported.
Results: Overall, 19 studies met the inclusion criteria. The majority of the studies were based in middle‑income 
countries and only three in low‑income settings. Most of the studies were conducted in Asia and only a handful 
in Sub‑Saharan Africa and Latin America. The reviewed studies mainly evaluated the integrated interventions, i.e. 
interventions consisted a combination of biomedical, structural or behavioural components. All interventions, except 
for one, were highly cost‑effective. The reporting quality of the evidence was relatively good. The strongest drivers of 
cost‑effectiveness, reported in the studies, were HIV prevalence, number of partners per sex worker and commodity 
costs. Furthermore, interventions integrated into existing health programs were shown to be most cost‑effective.
Conclusion: This review found that there is limited economic evidence on HIV and SRH interventions targeting sex 
workers. The available evidence indicates that the majority of the HIV and SRH interventions targeting sex workers are 
highly cost‑effective, however, more effort should be devoted to improving the quality of conducting and report‑
ing cost‑effectiveness evidence for these interventions to make them usable in policy making. This review identified 
potential factors that affect the cost‑effectiveness and can provide useful information for policy makers when design‑
ing and implementing such interventions.
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Introduction
In past 2 decades, international agencies, in particular 
the United Nations and the Global Fund, have intensified 
their efforts on prevention of infectious diseases, espe-
cially HIV, through improving access to preventive and 
curative care [1]. The reasons for this are both humani-
tarian and financial, with sexually transmitted infections 
(STIs) known to hinder economic growth in low and 
middle income countries (LMICs), particularly in Sub-
Sharan Africa, due to increased morbidity and mortal-
ity, as a result reducing labor supply and productivity [2]. 
In high-income, such as the Unites States, annual direct 
medical costs of sexually transmitted diseases (STDs) are 
estimated to be between USD 14 and USD 23 billion [3]. 
In past few decades, many strategies have been devel-
oped to control spread of HIV and STDs which include 
different forms of behavioural change and communica-
tion; condom promotion and distribution; voluntary 
counselling and testing; harm reduction strategies among 
drug users; STI prevention and treatment, antiretroviral/
therapy (ART), mother-to-child transmission prevention 
interventions, pre-exposure prophylaxis (PrEP) and many 
other interventions. Evidence has shown that an appro-
priate mix of these interventions can lead to significant 
reductions in the prevalence of HIV and STDs [4–6].
Focusing on target groups with the highest rates 
of HIV, such as sex workers, has shown to have large 
impacts on reducing transmission to the whole popula-
tion, and therefore, is likely to be highly cost-effective [7]. 
Sex workers, who defined as a population who exchange 
sex for money, goods or favours, are at a higher risk of 
adverse sexual health outcomes both due to their nature 
of work, their extraordinary social and economic vulner-
ability, and the high levels of stigma and violence attached 
to their work [8, 9]. Moreover, marginalised populations 
such as sex workers face many barriers accessing Sexual 
Reproductive Health (SRH) services due to reasons such 
as criminalisation of sex work, stigmatization and dis-
crimination experienced at health facilities, increasing 
their vulnerability and obstructing their right to access 
health services [9–12]. Furthermore, sex workers lack 
of contact with SRH services is also influenced socio-
demographics and the low levels of knowledge about the 
value of SRH interventions; for example, up to 26% of sex 
workers in Nigerian brothels were unaware of methods to 
protect against STIs [10, 13]. Interventions targeting bar-
riers in access to SRH services amongst sex workers have 
shown to be very effective in reducing prevalence of HIV 
and STIs [14].
Several authors [14–16] have systematically reviewed 
the evidence for the cost-effectiveness of SRH interven-
tions, especially HIV prevention strategies, aimed at the 
general population and concluded that there is limited 
economic evidence for some of the interventions as no 
economic analysis has been performed about these inter-
ventions, but for those that there was evidence many of 
them were cost-effective. However, evidence on what 
SRH interventions are most cost-effective amongst sex 
workers, the drivers of cost-effectiveness and the impact 
on the general population have rarely been evaluated 
[17].
The aim of this study was to systematically review the 
published evidence on cost-effectiveness of SRH inter-
ventions targeting sex workers. This review also aimed to 
assess the quality of the evidence and to identify the main 
drivers of the cost-effectiveness results amongst these 
interventions.
Methods
Search strategy
A literature search was conducted on Medline, Web of 
Science, Econlit and the NHS Economic Evaluation Data-
base. The keywords used were divided into three groups: 
“cost-effectiveness”, “sexual reproductive health interven-
tion” and “sex worker”. The full keywords used are shown 
in the Additional file 1, these were used in combination 
with each other.
Inclusion and exclusion criteria
We included studies that were published from Janu-
ary 1995 to May 2018 in English, with a full economic 
evaluation, i.e. studies performed comparative analysis 
of costs and outcomes of at least two interventions. Full 
economic evaluation analyses include cost minimiza-
tion analysis (CMA), cost-effectiveness analysis (CEA), 
cost-utility analysis (CUA) or cost–benefit analysis (CBA) 
[18]. We included the studies that specifically focused 
on sex workers or presented separate cost-effectiveness 
results for sex workers. Interventions included were all 
types of SRH interventions including preventative, cura-
tive or education or information provision that were tar-
geted towards improving the SRH of sex workers. The full 
exclusion and inclusion criteria are presented in detail in 
Additional file 2.
Data extraction and quality assessment
Relevant papers were selected in two steps: in first step, 
titles and abstracts of papers were screened and in sec-
ond step entire papers were screened according to the 
inclusion criteria. The papers were screened indepen-
dently by GR and HHB and disagreements were resolved 
by discussion.
A detailed analysis of the selected papers was car-
ried out using a tool that was adapted from the existing 
guidelines and other review articles of economic evalu-
ations [18–20]. Using this tool, general information and 
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economic features of the selected papers were extracted. 
The summary table of these features can be seen in 
Table 1 and full details are presented in Additional file 3.
The interventions included in this review were classified 
into four main categories: behavioral, biomedical, struc-
tural and mixed interventions. The behavioral or behav-
ior change interventions aim to reduce the risk of HIV/
STD infection through modification of sexual and sub-
stance use-related behaviors [21, 22]. These interventions 
seek to delay onset of sexual intercourse, decrease the 
number of sexual partners, reduce incidence of unpro-
tected sex, reduce sharing of needles and syringes, and 
reduce or eliminate substance use. These interventions 
generally focus on counseling individuals, couples, peer 
groups or networks, institutions, and entire communities 
through different means such as peer groups, workshops, 
social networks, social marketing or mass media [21, 22]. 
Biomedical interventions use chemical and physical tech-
nology to prevent infection or decrease infectiousness, 
through targeting biological and physiological processes 
that are responsible for HIV acquisition and transmis-
sion. These include interventions such as male and female 
condoms, treatment of STIs, pre- or post-exposure 
prophylaxis, ART, male circumcision, microbicides, and 
vaccines [21, 23]. Structural interventions, also known 
as social, environmental, ecological, or upstream inter-
ventions, aim to change the underlying determinants of 
risk, vulnerability or disease. These interventions, which 
are varied in nature, include legal changes, microfinance, 
vouchers, women empowerment, income-generating 
activities, etc. [21, 24]. Mixed or integrated interventions 
are those interventions that consisted a combination of 
biomedical, structural, or behavioral strategies.
The quality of reporting the economic evaluation 
evidence was assessed using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) 
checklist [25]. Twenty-four items of the checklist were 
scored using ‘yes’ (met the criteria in full), ‘partially met’, 
‘no’ (not met), and ‘not applicable’. GR and HHB indepen-
dently assessed the papers using the checklist and any 
discrepancies were resolved by discussion.
Interpreting cost‑effectiveness of the interventions
The cost-effectiveness of the interventions was judged 
using the WHO recommendation on cost-effectiveness 
threshold stating that an intervention is highly cost-effec-
tive if cost-effectiveness ratio (cost per DALY averted) 
is less than the GDP per capita, is cost-effective if it is 
between one and three times the GDP per capita and it 
is not cost-effective if it is more than triple the GDP per 
capita [26]. In addition to the WHO recommendation, 
the cost-effectiveness results were judged using alterna-
tive thresholds, stating that an intervention, in low and 
middle income countries, is cost-effective if the cost-
effectiveness ratio is < 50% of GDP per capita [27]. The 
outcomes reported in the studies, mainly in terms of cost 
per disability-adjusted-life-years (DALYs) averted, cost 
per quality-adjusted-life-years (QALYs) gained or cost 
per HIV infection (or STI) averted, were used in a cross-
study comparison. For the studies that only reported cost 
per infection averted, the cost per infection averted was 
converted to cost per DALYs averted, using a conversion 
Table 1 Summary of economic features of the studies
CUA cost-utility analysis, CEA cost-effectiveness analysis, CMA cost-minimisation 
analysis, CBA cost-benefit analysis, QALY quality-adjusted life year, DALY 
disability-adjusted life year
Feature N %
Type of economic evaluation
 CEA 8 42
 CUA 11 58
 CMA 0 0
 CBA 0 0
Study design
 Randomised clinical trial (RCT) 0 0
 Observational 4 21
 Modelling 15 79
Perspective evaluated
 Government/public sector 4 21
 Provider 8 42
 Program provider 2 11
 Not specified 5 26
Time horizon
 ≤ 1 year 4 21
 1–10 years 4 21
 Over 10 years/lifetime 5 26
 Not specified 6 32
Type of outcome
 QALY/DALY 11 58
 Infection averted 12 63
 Infections cured 3 16
Level of care and intervention type
 Behavior change 1 5
 Biomedical interventions 4 21
 Structural interventions 1 5
 Mixed 13 68
Type of data used
 Primary data 2 11
 Secondary data 15 79
 Mixed 2 11
Type of sensitivity analysis
 One‑way/univariate 12 63
 Multi‑way/multivariate 8 42
 Probabilistic analysis 6 32
 Not performed/specified 2 11
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factor used by previous studies [16, 28, 29] (i.e. it was 
assumed that cost per DALY averted was equal to cost 
per infection averted divided by 20). To facilitate the 
cross-study comparison, all cost-effectiveness ratios were 
inflated to 2016 values using the consumer price indices 
for the country where the study conducted and then con-
verted to 2016 international dollar (INT$) using the 2016 
Purchasing power parity (PPP) conversion factor for each 
country [30].
Results
Search results
The literature search identified a total of 6627 papers 
(Fig. 1). Initial title and abstract scanning excluded par-
tial economic evaluations (i.e. cost description, cost 
of illness studies) and identified studies that provided 
data for sex workers. Through this process 27 poten-
tial papers were identified and analyzed and eight were 
excluded either due to lack of cost data, appropriate 
outcome or separate sex worker results. The reference 
lists for the remaining 19 studies [31–49] were scanned 
for other possible studies.
General and economic features of the papers
The majority (74%, N = 14) of 19 included studies were 
based in middle-income countries with the exception of 
three low-income and two high-income settings. Most 
of the studies were conducted in Asia (48%, N = 10) fol-
lowing by sub-Saharan Africa (25%, N = 5).
A majority of the studies (58%, N = 11) were CUA, 
using DALYs (n = 8) or quality-adjusted life years 
(QALYs, n = 3) as the outcome measures. The remain-
ing were CEA, using cases of infection prevented as 
the outcome. Overall, 15 out of the 19 (79%) studies 
employed modeling, four were observational studies, 
and there was no randomized control trial design. The 
perspectives were mostly provider (42%, N = 8) fol-
lowed by government/public sector perspective (21%, 
N = 4), and five studies didn’t specify their perspective.
Six studies (32%) did not specify time horizon, 5 
(26%) studies had a time horizon of over 10  years, 4 
(21%) studies had a time horizon of 1–10  years and 4 
(21%) had a time horizon of < 1  year. There was one 
behavioral intervention, which consisted of voluntary 
counseling and testing, 4 (21%) biomedical interven-
tions, including STI test and treatment, HIV vaccina-
tion, introducing female condom, and 1 (5%) structural 
interventions, including provision of vouchers for 
sex workers. Furthermore, there were 13 (68%) mixed 
interventions, which consisted of either all three types 
of interventions or a combination of two. Majority of 
(n = 8, 62%) of mixed intervention included a combina-
tion of behavioral and biomedical strategies. Detailed 
features of the selected studies are reported in Addi-
tional file 3 and summarized in Table 1.
Quality of reporting the evidence
The findings of the assessment of reporting quality 
using the CHEERS checklist are presented in Addi-
tional file 4 and summarized in Table 2 and Fig. 2. The 
findings showed that on average, the compliance with 
each item on the CHEERS checklist was 62% (rang-
ing from 8 to 100%). The most frequently not reported 
items were item 9 ‘discount rate’ (47% compliant), item 
11b ‘measurement of effectiveness in synthesis-based 
estimates’ (10% compliant) and item 12 ‘measurement 
and valuation of preference based outcome’ (33% com-
pliant). Furthermore, item 15 ‘choice of model’ (46% 
compliant) and item 17 ‘describing analytical models’ 
(8% compliant) were major areas of weakness for the 
included studies.Fig. 1 Literature search flowchart
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Cost‑effectiveness by intervention type, income level 
and geographical region
Table  3 presents the cost-effectiveness results of the 
selected studies, classified based on the intervention type 
and ranked according to incremental cost-effectiveness 
ratios (ICERs). Except for one study (that evaluated reg-
ular mandatory STIs testing for sex workers in Victoria, 
Australia [48] which was not cost-effective), all other 
interventions were highly cost-effective, according to the 
WHO threshold [26] as well as Woods et al.’s [27] alterna-
tive threshold of ICER less than 50% of GDP per capita.
There was only one behavioral intervention (included 
promoting voluntary counseling and testing and condom 
use components), implemented in West-Java [44] which 
costs INT$33 per DALY averted (or INT$889 per HIV 
infection averted).
Four studies (21%) evaluated cost-effectiveness of bio-
medical interventions. In this category, a facility-based 
STI case management study in a province in Colombia by 
Carrara et  al. [34] showed that the cost per STI treated 
was INT$658. Contrastingly, Wilson et  al. [48] demon-
strated that the current scheme in Australia for sex work-
ers’ STI checkups costs the government INT$4,078,956 
per HIV infection averted, which, is not cost effective.
Only one study (5%) implemented structural interven-
tions, which was a competitive voucher scheme in Mana-
gua, Nicaragua to increase STI testing and treatment 
uptake in high-risk groups (such as female sex workers 
and their clients, transvestites etc.) [32]. ICER for this 
intervention was INT$364 per STI cured.
The ICER among the remaining 13 (48%) mixed inter-
ventions ranged from INT$51 per DALY averted (or 
INT$869 per HIV infection averted) in a district in 
India, for adding a structural component (i.e. community 
empowerment and involvement in programme manage-
ment and services, violence reduction, and addressing 
legal policies and police practices) to existing behavioral 
and biomedical strategies [45], to INT$3017 per DALY 
averted (INT$71,747 per HIV infection averted) in Santo 
Domingo district in Dominican Republic, for an inter-
vention package consisted of community mobilization 
activities (such as educational workshops and materials), 
promotional media (such as posters and stickers to rein-
force the message that the sex establishments were ‘‘100% 
condom’’ settings), and interpersonal communication 
(such as informational booths, and interactive theater 
presentations, training sex workers as health educators/
counselors and peer facilitators in STI clinics) [43].
With the exception of the Wilson et  al. study [48] in 
Australia, in all reviewed settings, the ICERs of all other 
interventions is < 20% of the GDP per capita, proving to 
be highly cost-effective interventions (Fig. 3). The ICERs 
of biomedical interventions were consistently less than 
2% of GDP per capita. Similarly, ICERs of the mixed 
interventions are on average 3% of GDP per capita (rang-
ing from 0.2 to 20%).
ICER of SRH interventions in low-income countries 
ranged from INT$4 to INT$33 per DALYs averted, com-
pared to INT$18–INT$3017 in middle income countries 
(Fig. 4). ICERs also varied in different geographical areas, 
the lowest in sub-Saharan Africa (on average, INT$98, 
ranging from INT$4 to INT$310) and the highest in 
Table 2 Number of studies fulfilling each CHEERS checklist 
items
Item Item no. Yes No Partially NA
Title and abstract
 Title 1 17 1 1 0
 Abstract 2 10 0 9 0
Introduction
 Background and objectives 3a 15 1 3 0
3b 17 0 2 0
Methods
 Target population and sub‑
groups
4 10 5 4 0
 Setting and location 5 15 2 2 0
 Study perspective 6 12 5 2 0
 Comparators 7 12 1 6 0
 Time horizon 8 10 6 3 0
 Discount rate 9 7 5 3 4
 Choice of health outcomes 10 10 0 9 0
 Measurement of effectiveness 11a 4 2 3 10
11b 1 3 6 9
 Measurement and valuation of 
preference based outcomes
12 1 1 1 16
 Estimating resources and costs 13a 4 1 1 13
13b 9 1 3 6
 Currency, price date, and conver‑
sion
14 11 5 3 0
 Choice of model 15 6 4 3 6
 Assumptions 16 11 2 0 6
 Analytical methods 17 1 12 0 6
Results
 Study parameters 18 15 2 2 0
 Incremental costs and outcomes 19 13 3 3 0
 Characterising uncertainty 20a 3 0 1 15
20b 13 0 2 4
 Characterising heterogeneity 21 8 5 1 5
Discussion
 Study findings, limitations, 
generalisability, and current 
knowledge
22 12 0 7 0
Other
 Source of funding 23 19 0 0 0
 Conflicts of interest 24 10 9 0 0
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Latin America (on average, INT$939, ranging from 
INT$18 to INT$3017) (Fig. 4).
Cost‑effectiveness by intervention structure and platform 
of delivery
Majority (n = 13) of the interventions evaluated in this 
review were stand-alone interventions and only five 
interventions were integrated into the existing programs. 
On average, ICER for the integrated interventions was 
INT$79 (ranging from INT$18 to INT$264), while ICER 
for stand-alone intervention was INT$469 (ranging from 
INT$4 to INT$3017) (Fig. 5).
Majority of the interventions were either delivered 
as outreach (n = 7) or at the clinic or health care facil-
ity (n = 6) and only five interventions were delivered 
using both platforms. Examining the ICER by platform 
of delivery indicated that on average mixed platform 
interventions had lower ICER, with INT$83 (ranging 
from INT$25 to INT$173), compared to clinic-based 
(with average ICER of INT$169, ranging from INT$18 to 
INT$301) and outreach (with average ICER of INT$634, 
ranging from INT$4 to INT$3017) interventions (Fig. 5).
Drivers of cost effectiveness
The drivers of cost-effectiveness were evaluated based 
upon the results from one-way/univariate sensitivity 
analyses. Most (89%, N = 17) studies conducted sensitiv-
ity analyses including one-way/univariate (63%, n = 12), 
multivariate (42%, N = 8) and probabilistic (32%, N =   6 
analyses. The remaining 2 (11%) studies did not perform 
or specify any sensitivity analysis. Additional file 5 sum-
marizes the results of the sensitivity analyses conducted 
in each study and the main drivers of cost effectiveness 
reported by the authors.
Studies showed [33, 40, 43] that the cost-effectiveness 
of HIV and SRH interventions for sex workers was most 
sensitive to HIV incidence and prevalence amongst sex 
workers. For example, Burgos et  al. [33] showed that 
when incidence of HIV amongst sex workers increased 
to 4% the cost per QALY decreased to 122$ per QALY 
gained whilst, when it fell to 0.3% the cost per QALY sub-
stantially increased (US$1202 per QALY gained). The 
number of partners per sex worker was also a recurring 
factor causing significant changes in cost-effectiveness 
results. Marseille et al. [40] reported that the numbers of 
partners per sex worker (or female condom user in this 
context) altered the cost-effectiveness results, indicating 
that more clients per year resulted in the female condom 
to be more cost saving. You et al. [49] demonstrated their 
results were sensitive to the number of clients per day 
and contact rate between female sex workers with their 
regular partners.
Commodity costs were another determinant factor in 
the cost-effectiveness in some studies. One study [47] 
reported that the cost of rapid diagnostic test was the 
largest determinant of the ICER. Changes in personnel 
Fig. 2 Quality of reporting economic evaluation of HIV and SRH interventions for sex workers per items of the CHEERS checklist. SRH sexual and 
reproductive health, CHEERS Consolidated Health Economic Evaluation Reporting Standards, N/A not applicable, No not reported, Yes reported
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costs and laboratory test prices caused significant 
changes in the cost-effectiveness outcomes in Borghi 
et  al. [32] study. Another driver of cost effectiveness 
results, which was mentioned in several studies, was the 
effectiveness of the intervention services provided such 
as the impact of voluntary counselling and testing (VCT) 
on condom use [44] or the actual effectiveness of female 
condoms in preventing STI transmissions [40].
Sweat et  al. [43] found that cost-effectiveness of HIV 
and SRH interventions are sensitive to the choice of dis-
count rate and marginally sensitive to STD prevalence 
in sex workers. However, Vassall et  al. [45] stated that 
variations in discount rate did not increase the incre-
mental cost per DALY averted above the cost-effective 
thresholds suggested by the WHO. In summary, the most 
important drivers to rendering a SRH intervention cost-
effective amongst sex workers is the high incidence and 
prevalence of HIV and other STIs, the average number 
of partners each sex worker has per year, and lastly, the 
commodity costs of the intervention.
Discussion
This is, to our best knowledge, the first study that has sys-
tematically reviewed the cost-effectiveness evidence of 
HIV and SRH interventions amongst sex workers, specif-
ically focusing on identifying the drivers of cost-effective-
ness. The findings of this study show that there is limited 
data on the cost-effectiveness of HIV and SRH interven-
tions among sex workers, in particular, new developed 
interventions such as PrEP. The findings also strongly 
Fig. 3 Cost per DALY averted vs. cost per DALY averted as % of GDP per capita, by intervention type. For studies that cost per DALY averted was not 
available, it was assumed that cost per DALY averted was equal to cost per infection averted divided by 20 [16, 28, 29]. Two studies [39, 48] used cost 
per QALY gained. Wilson et al. [48] study was outlier (with ICER of over INT$10 million) and was not included in the graph. Hogan et al. [37] study 
was not included as it was provided modeled estimates for two WHO regions and it was difficult to convert these estimated to 2016 international 
dollar. Separate ICER was included for the studies [43, 45] that reported ICER separately for the cities/districts the intervention implemented
Fig. 4 Comparing average cost‑effectiveness ratios of the 
interventions based on the income level and geographical region. 
For studies that cost per DALY averted was not available, it was 
assumed that cost per DALY averted was equal to cost per infection 
averted divided by 20 [16, 28, 29]. Two studies [39, 48] used cost per 
QALY gained. Wilson et al. [48] study was outlier (with ICER of over 
INT$10 million) and was not included in the graph. Hogan et al. [37] 
study was not included as it was provided modeled estimates for 
two WHO regions and it was difficult to convert these estimated to 
2016 international dollar. Separate ICER was included for the studies 
[43, 45] that reported ICER separately for the cities/districts the 
intervention implemented
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suggest that HIV and SRH interventions for sex workers 
are highly cost-effective as per international and national 
cost-effectiveness thresholds. The findings also suggest 
that quality of reporting evidence was relatively good but 
needs improvement in some areas. Moreover, the find-
ings showed that the main drivers of cost-effectiveness 
of the interventions were HIV incidence and prevalence 
amongst sex workers, number of sexual partners of sex 
workers, and commodity costs.
The findings demonstrate that all HIV and SRH inter-
ventions targeted at sex workers were highly cost-effec-
tive except for one. This is consistent with previous 
reviews evaluating cost-effectiveness of HIV preven-
tion strategies in the general population [16]. The cost-
effectiveness of the interventions was partially attributed 
to economies of scale and synergies caused by bundling 
several interventions together under one program or 
adding the new interventions to the existing programs. 
Most studies evaluated a package of prevention or pre-
vention and treatment interventions and around a third 
of the interventions integrated to the current health care 
system or programs on the ground (Additional file 3). For 
example, Dandona et al. [35], evaluated a program con-
sist of behaviour change, STI care, condom promotion, 
and creating an enabling environment components, and 
Fung et  al. [36] evaluated a strategy that includes STI 
treatment, peer education and condom distribution.
The findings also suggest that quality of report-
ing cost-effectiveness evidence is not ideal and needed 
to be improved in order to provide a useful source of 
information for decision makers. The specific areas for 
improvement identified by this review are justification for 
the choice of model and clear description of underpinned 
assumptions, transparency in synthesizing the clinical 
effectiveness data, specifying the time horizon, and the 
perspective of evaluation. In addition, it is recommended 
that future studies use comprehensive measures such 
as DALY or QALY, as gold standard measurements, to 
allow comparability across broad range of diseases [18] 
and adopt a societal perspective (instead of narrower 
perspectives, such as payer or provider) in order to facili-
tate optimal resource allocation decisions [50, 51] and 
enhance the comparability across different sectors.
The main drivers of cost effectiveness reported in the 
reviewed papers were HIV incidence and prevalence 
amongst sex workers, numbers of partners per sex worker, 
and commodity costs. This is in line with the results of a 
previous systematic review which reported that cost-effec-
tiveness of HIV prevention strategies was sensitive to the 
population targeted, the size of the intervention, and the 
unit costs [16]. Additionally, Cohen et al. [7] found that the 
drivers of cost effectiveness of HIV prevention interven-
tions were HIV prevalence and cost per person reached.
As mentioned earlier, other potential factors that might 
affect the cost-effectiveness of the interventions, due to 
economies of scope, are bundling the interventions together 
under one program as well as embedding the new interven-
tions to the existing programs (Figs. 3 and 5). For instance, 
the interventions that were integrated to the existing pro-
grams, on average, were more cost-effective than the stand-
alone interventions (Fig.  5). A stand-alone intervention 
might result in greater costs as it does not have the capital, 
infrastructure and staffing support of an established service, 
therefore, is often thought to be less sustainable [52]. More-
over, this supports the idea that integrated programs can 
be more cost-effective due to the ability to originate from 
scaling-up existing programs to reach desirable populations 
such as sex workers [53]. Similarly, whether the intervention 
is an outreach or clinic/facility based or mixed intervention 
might affect the cost-effectiveness results. Mixed outreach 
and facility-based interventions, on average, were more 
cost-effective than pure outreach interventions (Fig. 5).
Potential limitations
This review has several potential limitations that should 
be considered when interpreting its findings. Firstly, it 
is not possible to differentiate which intervention types 
are more cost-effective than others, since the studies 
reviewed did not take into account interactions between 
different types of interventions. Moreover, the cost-effec-
tiveness of each intervention is not directly compared, 
so it is difficult to determine the optimal interven-
tion. Further analyses, including modelling, are needed 
to comparatively assess the cost-effectiveness of each 
0
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Fig. 5 Comparing average cost‑effectiveness ratios of the 
interventions based on the structure (stand‑alone vs. integrated) 
and platform of delivery (clinic‑based vs. outreach‑based or mixed). 
For studies that cost per DALY averted was not available, it was 
assumed that cost per DALY averted was equal to cost per infection 
averted divided by 20 [16, 28, 29]. Two studies [39, 48] used cost per 
QALY gained. Wilson et al. [48] study was outlier (with ICER of over 
INT$10 million) and was not included in the graph. Hogan et al. [37] 
study was not included as it was provided modeled estimates for 
two WHO regions and it was difficult to convert these estimated to 
2016 international dollar. Separate ICER was included for the studies 
[43, 45] that reported ICER separately for the cities/districts the 
intervention implemented
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intervention in the same population to determine which 
intervention is most cost-effective. In addition, compari-
sons of the results between different studies and coun-
tries are problematic since the interventions evaluated 
are not homogenous, and cost-effectiveness results are 
influenced by a variety of factors such as epidemiological 
characteristics, coverage, unit prices or supply costs and 
the technical efficiency for implementation.
There are also few potential limitation in regards to 
the literature review process that need to be considered. 
This study only included published studies implying that 
the results might have skewed by publication bias. Fur-
thermore, as in any review study, it is difficult to rule 
out selection bias or disagreement between the criteria 
of the reviewers. To minimize this bias, we used pre-
defined inclusion criteria and discussion of disagreement 
between the investigators throughout the review process. 
Lastly, for cross study comparison, we used a conversion 
factor of 20 to convert cost per infection averted to cost 
per DALYs averted for the studies that cost per DALY 
averted was not available (n = 8). This conversion factor, 
has been widely used in the literature [16, 28, 29] and 
originated from the 1996 Global Burden of Disease [54] 
study when the HIV epidemic did not necessarily have 
the same characteristics as the present time. Research to 
create a contemporary conversion factor to convert non-
DALY estimates to cost per DALY ratios is ongoing [55].
Conclusion
The findings of this review show that there is limited 
economic evidence on HIV and SRH interventions tar-
geting sex workers. The available evidence indicates that 
the majority of the interventions are highly cost-effec-
tive considering national and internationally recognized 
thresholds, however, more effort should be devoted to 
improving the quality of (conducting and) reporting 
cost-effectiveness evidence for these interventions to 
make them usable in policy making. This review identi-
fied potential factors that affect the cost-effectiveness and 
can provide useful information for policy makers when 
designing and implementing such interventions.
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